CALIX, INC (CALX) SEC Filings, Jan-Feb 2026

Calix Chief Product Officer Shane Eleniak received a grant of stock options covering 195,000 shares of common stock. The options have an exercise price of $39.68 per share.

The award was originally granted on January 31, 2025 as a performance-based option. On February 12, 2026, the Compensation Committee confirmed that the performance criteria for 100% of the grant had been achieved. The option vests 25% on January 31, 2026, with the remaining 75% vesting in equal quarterly installments over 36 months from that date, subject to Eleniak’s continued employment with Calix.

SINDELAR CORY reported acquisition or exercise transactions in a Form 4 filing for CALX. The filing lists transactions totaling 170,439 shares at a weighted average price of $45.32 per share. Following the reported transactions, holdings were 103,994 shares.

Calix director and 10% owner Carl Russo reported indirect stock sales through a trust. On February 3, 2026, The Crescentico Trust, for which Russo serves as trustee, sold 13,477 Calix common shares at a weighted average price of $46.9338 and 11,523 shares at a weighted average price of $47.658, under a pre-established Rule 10b5-1 trading plan adopted on April 25, 2025.

After these transactions, 1,669,188 Calix shares were indirectly held by The Crescentico Trust. Separately, 13,782 shares were indirectly held by Equanimous Investments, an entity whose managing members include Russo and Tim Pasquinelli and for which each individual disclaims beneficial ownership except to the extent of his pecuniary interest. Russo also reported 3,983,070 Calix shares held directly.

Calix, Inc. Chief Financial Officer Cory Sindelar reported exercising stock options and receiving additional common shares. On February 2, 2026, he exercised a stock option for 27,000 shares at an exercise price of $5.05 per share, increasing his direct common stock holdings to 103,555 shares.

The option transaction, reported as a derivative security, left him with 148,000 stock options beneficially owned after the exercise. According to the footnote, all shares subject to this option were fully vested and exercisable as of October 1, 2021.

Calix insider plans to sell 25,000 common shares under Rule 144. The shares are held for the account of a reporting person and are to be sold through Wells Fargo Clearing Services on the NYSE, with an approximate sale date of 02/03/2026 and an aggregate market value of 1,180,432.28.

The 25,000 shares were acquired on 01/30/2023 via stock options from the issuer, paid in cash on the same date. The notice also lists sales during the past three months, including 25,000 shares sold by Crescentico Trust and 395,000 shares sold by Carl Russo, with stated gross proceeds.

Calix, Inc. filed a current report noting it has released a press release and a detailed stockholder letter presenting its financial results for the fourth quarter ended December 31, 2025. Both documents are attached as exhibits.

The stockholder letter highlights several non-GAAP metrics, including non-GAAP gross margin, operating expenses, functional investment categories, effective income tax rate, net income, net income per diluted share and free cash flow. Calix explains these measures exclude non-cash stock-based compensation, intangible asset amortization and certain income tax effects, and are used by management to evaluate performance and set operational goals. Reconciliations to the most comparable U.S. GAAP figures are provided in tabular form in the stockholder letter.

Calix, Inc. expanded its stock repurchase program, which had $109.3 million of remaining authorization as of December 31, 2025. On January 27, 2026, the board approved up to an additional $125 million of buybacks, bringing the total program authorization to $425 million.

The company may repurchase shares from time to time through open market purchases, privately negotiated transactions or other methods, in line with SEC rules and its capital allocation strategy. Calix is not required to repurchase a specific amount of stock and may suspend or discontinue the program at its discretion.

Calix, Inc. director and 10% owner Carl Russo reported an option exercise involving company stock. On January 7, 2026, he exercised a stock option to acquire 10,000 shares of Calix common stock at $12.63 per share, converting a derivative position into directly held shares. Following this transaction, he directly held 3,983,070 shares of common stock and 570,000 stock options.

Additional Calix shares are reported as indirectly owned through The Crescentico Trust, where Russo is trustee, and through Equanimous Investments, an entity managed by Russo and Tim Pasquinelli. The filing states that these individuals may be deemed to share voting and investment power over Equanimous Investments’ shares and that each disclaims beneficial ownership except to the extent of his pecuniary interest. The option exercised for 10,000 shares was fully vested and exercisable as of May 22, 2024.

Calix, Inc. director and 10% owner Carl Russo reported an automatic grant of employee stock options on common stock. The filing shows an award of 11,663 stock options with an exercise price of $53.59 per share, dated January 2, 2026. These options begin to vest with respect to 25% of the underlying shares on each anniversary of the grant date, starting one year after January 2, 2026, and are listed as exercisable from January 2, 2027 until expiration on January 2, 2036. Following this grant, Russo is shown as directly holding 11,663 derivative securities tied to Calix common stock.